Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
Uložené v:
| Názov: | Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study |
|---|---|
| Autori: | S. Krajnak, C. Schnatz, K. Almstedt, W. Brenner, F. Haertner, A.-S. Heimes, A. Lebrecht, G.-M. Makris, R. Schwab, A. Hasenburg, M. Schmidt, M. J. Battista |
| Prispievatelia: | Johannes Gutenberg-Universität Mainz |
| Zdroj: | Breast Cancer Res Treat |
| Informácie o vydavateľovi: | Springer Science and Business Media LLC, 2020. |
| Rok vydania: | 2020 |
| Predmety: | Adult, Aged, 80 and over [MeSH], Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents/administration, Breast Neoplasms/therapy [MeSH], Neoadjuvant Therapy/methods [MeSH], Administration, Oral [MeSH], Cyclophosphamide/administration, Case-Control Studies [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Dose-Response Relationship, Drug [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Receptors, Progesterone/metabolism [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Clinical Trial, Retrospective Studies [MeSH], Middle Aged [MeSH], Administration, Metronomic [MeSH], Oncology, Methotrexate/administration, Mastectomy [MeSH], Receptor, ErbB-2, 610 Medizin, Administration, Oral, Antineoplastic Agents, Breast Neoplasms, Kaplan-Meier Estimate, 03 medical and health sciences, 0302 clinical medicine, 610 Medical sciences, Humans, Cyclophosphamide, Mastectomy, Aged, Aged, 80 and over, ddc:610, Dose-Response Relationship, Drug, Middle Aged, Neoadjuvant Therapy, Progression-Free Survival, 3. Good health, Methotrexate, Chemotherapy, Adjuvant, Case-Control Studies, Administration, Metronomic, Female |
| Popis: | Purpose There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. Methods Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. Results 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). Conclusions We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients. |
| Druh dokumentu: | Article Other literature type |
| Jazyk: | English |
| ISSN: | 1573-7217 0167-6806 |
| DOI: | 10.1007/s10549-020-05711-5 |
| DOI: | 10.25358/openscience-5969 |
| Prístupová URL adresa: | https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf https://pubmed.ncbi.nlm.nih.gov/32495001 https://link.springer.com/content/pdf/10.1007/s10549-020-05711-5.pdf https://pubmed.ncbi.nlm.nih.gov/32495001/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297707 https://link.springer.com/article/10.1007/s10549-020-05711-5 https://europepmc.org/article/PMC/PMC7297707 https://repository.publisso.de/resource/frl:6470722 |
| Rights: | CC BY |
| Prístupové číslo: | edsair.doi.dedup.....83a1fdb0ed360b252d8df0ace76a51e8 |
| Databáza: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Purpose There is growing interest in low-dose metronomic chemotherapy (LDMC) in metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared the efficacy of LDMC and conventional chemotherapy (CCT) in MBC. Methods Each LDMC patient receiving oral cyclophosphamide (CTX) (50 mg daily) and methotrexate (MTX) (2.5 mg every other day) was matched with two controls who received CCT. Age, number of chemotherapy lines and metastatic sites as well as hormone receptor (HR) status were considered as matching criteria. Primary endpoint was disease control rate longer than 24 weeks (DCR). Secondary endpoints were progression-free survival (PFS), duration of response (DoR) and subgroup analyses using the matching criteria. Results 40 cases and 80 controls entered the study. 30.0% patients with LDMC and 22.5% patients with CCT showed DCR (p = 0.380). The median PFS was 12.0 weeks in both groups (p = 0.218) and the median DoR was 31.0 vs. 20.5 weeks (p = 0.383), respectively. Among younger patients, DCR was 40.0% in LDMC vs. 25.0% in the CCT group (p = 0.249). DCR was achieved in 33.3% vs. 26.2% non-heavily pretreated patients (p = 0.568) and in 36.0% vs. 18.0% patients without multiple metastases (p = 0.096), respectively. In the HR-positive group, 30.0% LDMC vs. 28.3% CCT patients showed DCR (p = 1.000). Among triple-negative patients, DCR was achieved in 30.0% LDMC and 5.0% CCT patients (p = 0.095). Conclusions We demonstrated a similar efficacy of LDMC compared to CCT in the treatment of MBC. Thus, LDMC may be a valuable treatment option in selected MBC patients. |
|---|---|
| ISSN: | 15737217 01676806 |
| DOI: | 10.1007/s10549-020-05711-5 |